Full Version -
Mesothelial cell proliferations that are not unequivocally malignant are termed atypical mesothelial proliferations or atypical mesothelial hyperplasia. Frequently, pathologists are challenged with regards to classifying such mesothelial proliferations as representing a malignancy (i.e. mesothelioma) or benign reactive hyperplasia. This presentation will focus on the combined use of p16INK4a FISH and BAP1 immunohistochemistry as a diagnostic tool for the evaluation of such atypical mesothelial proliferations. A short overview of the diagnostic work-up of mesothelioma versus benign reactive mesothelial proliferations will be presented as well. Lastly, the impact on patient care for BAP1 and P16 FISH testing in this setting will be discussed.
- Review of atypical mesothelial proliferations versus mesothelioma from a pathologist point of view.
- Diagnostic use of BAP1 IHC and p16 FISH will be discussed.
- Immunohistochemical and molecular testing for diagnosis of mesothelioma will be reviewed.
- Criteria for diagnosis of mesothelioma will also be reviewed and discussed.
Leica Biosystems webinars, training presentations and related materials provide general information regarding particular subjects and are not intended to be, and should not be construed as medical, regulatory or legal advice. The views and opinions expressed are the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents.
For the use of any product, the product information guides, inserts and operation manuals of the various products and devices should be consulted. Leica Biosystems and the editors disclaim any liability arising directly or indirectly from the use of devices, techniques or procedures described in these materials.
Copyright © 2019 by Leica Biosystems Richmond Inc. All rights reserved.LEICA and the Leica Logo are registered trademarks of Leica Microsystems